
1. Vaccine. 2021 Nov 26;39(48):6975-6979. doi: 10.1016/j.vaccine.2021.10.058. Epub
2021 Oct 29.

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA
COVID-19 vaccine: A case-control study.

García-Grimshaw M(1), Ceballos-Liceaga SE(2), Michel-Chávez A(3), García-Alanis
M(3), Cadena-Fernández A(3), Galnares-Olalde JA(4), Carbajal-Sandoval G(2),
Carrillo-García DA(2), Hernández-Valdivia N(2), Hernández-Vanegas LE(4),
Saniger-Alba MDM(3), Gutierrez-Romero A(4), Díaz-Ortega JL(5), Reyes-Terán G(6), 
López-Gatell H(7), Flores-Silva FD(3), Cantú-Brito C(3), Chiquete E(3), Arauz
A(4), Valdés-Ferrer SI(8).

Author information: 
(1)Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas
y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address:
miguel.garciag@incmnsz.mx.
(2)Dirección General de Epidemiología, Secretaría de Salud, Gobierno de México,
Mexico.
(3)Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas
y Nutrición Salvador Zubirán, Mexico City, Mexico.
(4)Department of Neurology, Instituto Nacional de Neurología y Neurocirugía
Manuel Velasco Suárez, Mexico City, Mexico.
(5)Centro Nacional para la Salud de la Infancia y la Adolescencia, Secretaría de 
Salud, Mexico City, Mexico.
(6)Comisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta
Especialidad, Secretaría de Salud, Mexico City, Mexico.
(7)Secretaría de Salud, Gobierno de México, Mexico.
(8)Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas
y Nutrición Salvador Zubirán, Mexico City, Mexico; Department of Infectious
Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Mexico City, Mexico; Feinstein Institutes for Medical Research, Manhasset, NY,
USA. Electronic address: sergio.valdesf@incmnsz.mx.

mRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy
is partly due to a misperception of their potential adverse events. Non-specific 
sensory symptoms (NSSS) following immunization are thought to be mediated by
stress-related responses. In this case-control study, we evaluated NSSS from a
cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an
adverse event following immunization (AEFI). We found an overall frequency of
3.4% (377 cases) or 4.8 cases per 100,000 doses administered. Anatomically, the
arms (61%) and face/neck region (36.2%) were the most commonly affected sites.
The control group had significantly higher rates of reactogenicity-associated
symptoms, suggesting that NSSS are reactogenicity-independent; in multivariable
analysis, healthcare workers reported sensory symptoms less frequently (aOR 0.54;
95% CI 0.40-0.72;p < 0.001). This is the first study describing the topography
and associated factors for developing NSSS among BNT162b2 recipients. The benign 
nature of these symptoms may help dissipate hesitation towards this vaccine.

Copyright © 2021 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.vaccine.2021.10.058 
PMCID: PMC8554108
PMID: 34742595  [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Competing Interest The authors
declare the following financial interests/personal relationships which may be
considered as potential competing interests: Sergio Ivan Valdes-Ferrer reports
financial support was provided by Consejo Nacional de Ciencia y Tecnología.

